Welcome to our dedicated page for Cosmos Health SEC filings (Ticker: COSM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cosmos Health Inc. (COSM) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, giving investors structured access to its official record as a Nasdaq Capital Market issuer. Cosmos Health describes itself as a diversified, vertically integrated global healthcare group, and its filings reflect activity in pharmaceuticals, nutraceuticals, manufacturing, distribution, telehealth and digital assets.
Key documents include annual reports on Form 10-K and quarterly reports on Form 10-Q, which present audited and interim financial statements, segment information tied to wholesale distribution, pharma manufacturing and branded products, as well as discussions of risk factors, liquidity and capital resources. Notifications such as the NT 10-Q filing explain delays in periodic reports and provide context on reporting timelines.
Cosmos Health also files numerous Current Reports on Form 8-K detailing material events. Recent 8-Ks cover topics such as record quarterly results, Nasdaq minimum bid price compliance notices, entry into a Securities Purchase Agreement for up to $300 million of senior secured convertible notes, the issuance of an initial $8 million note, governance and board changes, and shareholder approvals to increase authorized share capital and authorize a potential reverse stock split. These filings help investors track financing structures, capital allocation and corporate governance decisions.
Proxy materials like the DEF 14A definitive proxy statement provide information on director elections, executive compensation, equity incentive plans and shareholder proposals, including approvals related to the note financing and changes in authorized shares. Together with Form 4 insider transaction reports referenced in company news, these documents allow users to monitor ownership changes and board-level decisions.
On Stock Titan, COSM filings are updated in near real time as they are posted to EDGAR. AI-powered summaries highlight the main points of lengthy 10-K and 10-Q reports, explain complex financing terms in 8-Ks, and surface items such as bid price compliance, convertible note terms and voting outcomes. Users can quickly locate Forms 10-K, 10-Q, 8-K, DEF 14A and Form 4 filings, then rely on AI insights to understand how each filing may relate to Cosmos Health’s operations, balance sheet, governance and listing status.
Cosmos Health Inc. CEO, director and 10% owner Grigorios Siokas acquired 388,532 shares of common stock on February 12, 2026. The shares were issued at $0.3732 per share in exchange for $145,000 of debt the company owed to him. Following this transaction, he directly owns 8,861,914 shares of Cosmos Health common stock.
Cosmos Health Inc. Chief Executive Officer, director and 10% owner Grigorios Siokas acquired 291,262 shares of common stock on February 11, 2026. The shares were obtained at $0.4120 per share in exchange for $120,000 of debt the company owed to him under a debt exchange agreement.
Following this transaction, Mr. Siokas directly beneficially owns 8,473,382 shares of Cosmos Health common stock.
Cosmos Health Inc. filed a Form 4 showing that CEO, director and 10% owner Grigorios Siokas acquired additional common shares through a debt-for-equity exchange. On January 23, 2026, he obtained 90,325 shares of common stock at $0.4982 per share, representing the fair market value that day, in exchange for $45,000 of debt the company owed him under a Debt Exchange Agreement. Following this transaction, he directly holds 8,182,120 common shares.
Cosmos Health Inc.'s Chief Executive Officer, director, and 10% owner Grigorios Siokas acquired additional common shares of the company through a debt exchange. On January 20, 2026, he obtained 353,321 shares of common stock at $0.4953 per share, described as the fair market value on that date. The shares were issued under a Debt Exchange Agreement in which $175,000 of debt the company owed to Mr. Siokas was exchanged for equity.
Following this transaction, Mr. Siokas beneficially owns 8,091,795 shares of Cosmos Health common stock in direct ownership. The filing characterizes the transaction with code "P" and notes that these shares are classified as Exchange Shares under the terms of the Debt Exchange Agreement.
Cosmos Health Inc.'s Chief Executive Officer, director and 10% owner Grigorios Siokas reported acquiring 493,495 shares of common stock on January 14, 2026. The shares were obtained at $0.4458 per share, described as the fair market value on that date, through a debt exchange agreement with the company.
Under this agreement, Mr. Siokas exchanged $220,000 of debt that the company owed him for these "Exchange Shares". Following the transaction, he beneficially owned 7,738,474 shares of Cosmos Health common stock in direct ownership.
Cosmos Health Inc. insider filing shows its CEO and 10% owner, Grigorios Siokas, acquiring 113,185 shares of common stock on January 12, 2026. The shares were obtained at $0.5036 per share under a Debt Exchange Agreement, using $57,000 of debt the company owed to him as payment instead of cash. After this transaction, he beneficially owns 7,244,979 common shares directly.
Cosmos Health Inc. insider transaction: Chief Executive Officer, director, and 10% owner Grigorios Siokas acquired 156,190 shares of Common Stock on January 8, 2026. The shares were obtained at $0.5186 per share pursuant to a Debt Exchange Agreement, in which $81,000 of debt that the company owed to Mr. Siokas was exchanged for stock at the fair market value on that date. Following this transaction, he beneficially owned 7,131,794 shares of Common Stock, held directly.
Cosmos Health Inc. director, chief executive officer, and 10% owner Grigorios Siokas reported acquiring common stock through a debt-for-equity exchange. On January 7, 2026, he acquired 124,880 shares of common stock at $0.5205 per share, identified as Exchange Shares under a Debt Exchange Agreement with the company. The shares were issued in exchange for $65,000 of debt the company owed to him, effectively converting that obligation into equity rather than a cash payment. Following this transaction, he beneficially owned 6,975,604 shares of the company’s common stock, held directly.
Cosmos Health Inc. CEO Grigorios Siokas acquired 133,953 common shares at $0.5375 per share on January 6, 2026. The shares were issued under a Debt Exchange Agreement in which $72,000 of debt the company owed to Mr. Siokas was exchanged for stock at the fair market value of the common shares on that date.
After this transaction, Mr. Siokas beneficially owned 6,850,724 shares of Cosmos Health common stock in direct ownership. He is reported as a director, chief executive officer, and a 10% owner of the company.
COSMOS HEALTH INC. reported that Nasdaq notified the company on December 11, 2025 that it is not in compliance with the Nasdaq Listing Rule requiring a minimum bid price of $1.00 per share for 30 consecutive business days. The company now has 180 calendar days from December 11, 2025 to regain compliance by keeping its common stock closing bid price at or above $1.00 per share for at least 10 consecutive business days.
If the company does not otherwise regain compliance with this listing standard, it states that it intends to implement a reverse stock split to meet the rule. Nasdaq will also display an indicator with quotation information related to the company’s securities, signaling the current non-compliance status to the market.
FAQ
What is the current stock price of Cosmos Health (COSM)?
What is the market cap of Cosmos Health (COSM)?
